A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

BCR-ABL1-STAT5 is an oncogenic signaling pathway in human chronic myelogenous leukemia (CML) and it represents a valid target for anti-CML drug design. Resistance to direct BCR-ABL1 inhibitors is a common clinical issue, so STAT5 inhibition has become an interesting alternative target. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Rodríguez, Patricia, Guerra, Borja, Hueso-Falcón, Idaira, Aranda-Tavío, Haidee, Díaz-Chico, Juan, Quintana, José, Estévez, Francisco, Díaz-Chico, Bonifacio, Amesty, Angel, Estévez-Braun, Ana, Fernández-Pérez, Leandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334626/
https://www.ncbi.nlm.nih.gov/pubmed/30687103
http://dx.doi.org/10.3389/fphar.2018.01546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334626/
https://www.ncbi.nlm.nih.gov/pubmed/30687103
http://dx.doi.org/10.3389/fphar.2018.01546

Ejemplares similares